Will the Bank of Canada cut interest rates? What economists expect

Joe Rogan, the popular podcast host, dropped a stark warning about a common food item many people likely have in their kitchens. While he didn’t specify which food, the implication is that it could be harmful or problematic—so much so that he’s urging listeners to take a closer look at their pantries.

Editor’s Note: Rogan’s massive platform means his warnings can spark widespread concern—or even panic—about everyday products. Whether this is a legitimate health risk or just his personal take, it’s bound to get people talking (and double-checking their groceries). If nothing else, it’s a reminder to stay critical about what we consume.

BlackRock’s investment experts are doubling down on US stocks, arguing that the American market is still the top pick for investors—even as global markets heat up. They’re calling it a "risk-on" environment, where confidence is high, and they believe US equities will outperform European ones.

Editor’s Note: When a giant like BlackRock leans into US stocks, it’s a signal that Wall Street’s momentum might not be slowing down anytime soon. For everyday investors, it’s a nudge to pay attention to where the big players are putting their money—especially if you’re weighing options between US and European markets.

Hyperion DeFi, previously known as Eyenovia, is making waves after a major rebrand—its stock price shot up following the name change. The company appears to be pivoting toward decentralized finance (DeFi), and investors are clearly betting on its new direction.

Editor’s Note: Rebranding can signal big strategic shifts, and in this case, the market seems optimistic about Hyperion DeFi's move into the fast-growing DeFi space. If the company successfully capitalizes on crypto and blockchain trends, this could be the start of a major turnaround—or just another hype-driven spike. Either way, it’s a sign of how quickly investor interest can shift when a company aligns itself with a hot sector.

Cytosorbents, a medical device company, saw its stock take a nosedive after hitting regulatory roadblocks for one of its flagship products. The setback means delays—or worse—for a device that was expected to be a major revenue driver. Investors clearly weren’t thrilled, and the market reaction was swift and brutal.

Editor’s Note: Regulatory hurdles are a make-or-break moment for medtech companies, and Cytosorbents just hit a major speed bump. This isn’t just about stock prices—delays like these can ripple out, affecting everything from investor confidence to patient access to new treatments. For a sector where timelines are everything, this kind of news stings.

Economist Veronique de Rugy isn’t mincing words about the Senate’s latest tax bill—she calls it "highly problematic" and argues lawmakers are dropping the ball on fiscal responsibility. In a Bloomberg Markets interview, she laid out her concerns, suggesting the bill could worsen the country’s financial health rather than stabilize it.

Editor’s Note: When a respected economist like de Rugy sounds the alarm on a major budget bill, it’s worth paying attention. Her critique isn’t just about partisan politics—it’s a warning that rushed or shortsighted fiscal decisions could have real consequences for the economy down the line. Whether you agree with her or not, it’s a reminder that how the government spends (or cuts) money affects everyone.